Carvedilol phosphate | CAS# 610309-89-2 | alpha/beta blocking activity

MedKoo Cat#: 412413 | Name: Carvedilol phosphate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carvedilol phosphate has alpha as well as beta blocking activity.

Chemical Structure

Carvedilol phosphate

CAS#610309-89-2 (phosphate)

Theoretical Analysis

MedKoo Cat#: 412413

Name: Carvedilol phosphate

CAS#: 610309-89-2 (phosphate)

Chemical Formula: C48H60N4O17P2

Exact Mass: 1026.3429

Molecular Weight: 1026.97

Elemental Analysis: C, 56.14; H, 5.89; N, 5.46; O, 26.48; P, 6.03

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

72956-09-3 (free base) 610309-89-2 (phosphate)

Synonym

Carvedilol phosphate; Coreg CR; SKF105517D; SKF-105517D; SKF 105517D

IUPAC/Chemical Name

bis(1-((9H-carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol) bis(phosphate) hydrate

InChi Key

LHNYXTULDSJZRB-UHFFFAOYSA-N

InChi Code

InChI=1S/2C24H26N2O4.2H3O4P.H2O/c2*1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20;2*1-5(2,3)4;/h2*2-12,17,25-27H,13-16H2,1H3;2*(H3,1,2,3,4);1H2

SMILES Code

COc1c(OCCNCC(COc(ccc2)c3c2[nH]c4c3cccc4)O)cccc1.COc5c(OCCNCC(COc(ccc6)c7c6[nH]c8c7cccc8)O)cccc5.OP(O)(O)=O.OP(O)(O)=O.O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,026.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Polonini H, da Silva SL, Brandão MAF, Bauters T, De Moerloose B, Ferreira AO. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4. Int J Pharm Compd. 2018 Nov-Dec;22(6):516-526. PMID: 30384353. 2: Allada R, Maruthapillai A, Palanisamy K, Chappa P. Moisture Sorption- desorption Characteristics and the Corresponding Thermodynamic Properties of Carvedilol Phosphate. J Pharm Bioallied Sci. 2017 Jan-Mar;9(1):16-21. doi: 10.4103/0975-7406.206216. PMID: 28584488; PMCID: PMC5450465. 3: Okumura K, Kato H, Honjo O, Breitling S, Kuebler WM, Sun M, Friedberg MK. Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. J Mol Med (Berl). 2015 Jun;93(6):663-74. doi: 10.1007/s00109-015-1251-9. Epub 2015 Jan 18. PMID: 25595602. 4: Oliveira PJ, Esteves T, Rolo AP, Palmeira CM, Moreno AJ. Carvedilol inhibits the mitochondrial permeability transition by an antioxidant mechanism. Cardiovasc Toxicol. 2004;4(1):11-20. doi: 10.1385/ct:4:1:11. PMID: 15034201. 5: Avachat AM, Patel KB, Rokade MS, Dash RR. Formulation and characterization of an expandable, gastroretentive system of carvedilol phosphate by 32 factorial design. PDA J Pharm Sci Technol. 2011 Jan-Feb;65(1):12-9. PMID: 21414936. 6: Yilmaz B, Arslan S. HPLC/Fluorometric Detection of Carvedilol in Real Human Plasma Samples Using Liquid-Liquid Extraction. J Chromatogr Sci. 2016 Mar;54(3):413-8. doi: 10.1093/chromsci/bmv157. Epub 2015 Nov 3. PMID: 26538492. 7: Yeh CH, Chen TP, Wang YC, Lin YM, Fang SW. Carvedilol treatment after myocardial infarct decreases cardiomyocytic apoptosis in the peri-infarct zone during cardioplegia-induced cardiac arrest. Shock. 2013 Apr;39(4):343-52. doi: 10.1097/SHK.0b013e31828c588a. PMID: 23481492. 8: Srikanth Meka V, Wee Liang VA, Dharmalingham SR, Sheshala R, Gorajana A. Preparation and in vitro characterization of non-effervescent floating drug delivery system of poorly soluble drug, carvedilol phosphate. Acta Pharm. 2014 Dec;64(4):485-94. doi: 10.2478/acph-2014-0038. PMID: 25531788. 9: Hashemzadeh M, Movahed MR, Russu WA, Soroush L, Hill DN. Novel design and synthesis of modified structure of carvedilol. Recent Pat Cardiovasc Drug Discov. 2011 Sep;6(3):175-9. doi: 10.2174/157489011797376988. PMID: 21834769. 10: Chakraborty S, Shukla D, Jain A, Mishra B, Singh S. Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. J Colloid Interface Sci. 2009 Jul 15;335(2):242-9. doi: 10.1016/j.jcis.2009.03.047. Epub 2009 Apr 5. PMID: 19403142.